摘要
目的观察甘露聚糖肽联合化疗治疗晚期小细胞肺癌(SCLC)的疗效、毒副反应及免疫功能的变化。方法41例晚期SCLC随机分为化疗加用甘露聚糖肽组(治疗组)和单用化疗组(对照组),分别接受EP方案(依托泊甙、顺铂)加甘露聚糖肽与单用EP方案化疗。结果治疗组有效率(RR)76.2%,对照组有效率60.0%(P<0.05);中位缓解期分别为11.2个月及9.9个月(P>0.05)。治疗组化疗前后免疫功能无明显变化(P>0.05),而对照组化疗后CD4及CD4/CD8值较化疗前下降,CD8较化疗前升高,差异有统计学意义(P<0.05)。毒副反应:治疗组白细胞减少57.1%,对照组95.0%。结论甘露聚糖肽与化疗联合应用治疗晚期SCLC疗效有所提高,可明显增强细胞免疫功能,对化疗引起的白细胞减少有保护作用。
Objective To evaluate the efficacy of mannatide plus NP chemotherapy in the treatment of SCLC,the immune function and side effects were also observed.Methods 41 patients with advanced small cell lung cancer were at randome divided into observation group（EP＋mannatide） and control group（only EP）.Results Recent curative effect was 76.2% in the observation group,60.0% in the control group（P〈0.05）.The median remission was 11.2 months in the observation group,9.9months in the control group（P〉0.05）.No obvious immune function change was found in the observation group（P〉0.05）,but after chemotherapy the decreasing of CD4^＋ and CD4^＋/CD8^＋ was found in the control group（P〈0.05）.Conclusion The curative effect of mannatide combinied with EP has improved in SCLC,mannatide can potentiate the immune function of patients and reverse the decrease of WBC count due to chemotherapy.
出处
《肿瘤基础与临床》
2009年第4期316-317,共2页
journal of basic and clinical oncology
